Pembrolizumab vs Nivolumab as Initial Treatment for Advanced, Unresectable, or Metastatic Melanoma

This comparative effectiveness research study examines outcomes associated with pembrolizumab and nivolumab among US veterans with advanced, unresectable, or metastatic melanoma.

Corresponding Author: Alex K. Bryant, MD, MAS, Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, 2215 Fuller Rd, Ann Arbor, MI 48105 (Alex.bryant@va.gov).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.